reports
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sha...
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy SALT LAKE CITY, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG). Kiora will trade on the Nasdaq Capital Market under the ticker symbol "KPRX" and CUSIP number 49721T101. The new brand reflects the Company’s aim to not only treat common eye conditions, but to develop a revolutionary small molecule therapy that has the potential to restore vision loss for a rare, inh...
EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief De...
EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc. EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that it has completed the planned acquisition of Bayon Therapeutics, Inc. (“Bayon...
EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investmen...
EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that EyeGate’s President and Chief Executive Officer, Brian M. Strem, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-...
EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept...
EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation -Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers- -Trial remains on track with topline data expected in Q4 2021- WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today ...
EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provi...
EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update WALTHAM, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today reported its financial results for the quarter ended June 30, 2021 and provided an update on recent corporate and operational activities. “In the second quarter of 2021 we made significant advancements to b...
EyeGate Announces Closing of $10.75 Million Registered Direct Offering...
EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules WALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today announced the closing of its previously announced registered direct offering priced at-the-marked under Nasdaq rules of 4,668,844 shares of its common stock at a purchase price of $2.3025...
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-...
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules WALTHAM, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale, in a registered direct offering priced at-the-marked under Nas...
- Jonathan Moreland
- Jonathan Moreland
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D....
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer -EyeGate signs non-binding letter of intent to acquire Bayon Therapeutics, a private ophthalmic pharmaceutical company developing a novel, vision restoring small molecule platform- WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced th...
EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 P...
EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation Study - Proof-of-concept study conducted in Austria--Topline data expected in Q4 2021- WALTHAM, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today announced the first patient dosed in phase II proof-of-concept (“POC”) study evaluating its lea...
EyeGate Pharma Reports First Quarter 2021 Financial Results and Provid...
EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update - PP-001: proof-of-concept study in Austria for dry eye patients expected to initiate in Q3:21; U.S. IND submission planned in Q4:21- -OBG: U.S. IND submission and initiation of Phase 2 dry eye study is planned in Q4:21; proof-of-concept study for persistent epithelial defects expected to initiate in Q4:21- -PP-001 for systemic indications: Phase 1 healthy volunteer study in Austria planned to initiate in Q4:21- WALTHAM, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:...
EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Sh...
EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors WALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it has appointed Kenneth Gayron and Aron Shapiro to the Company’s Board of Directors, effective immediately. Thomas Hancock, Morton Goldberg, M.D., and Bernard Malfroy-Camine, Ph.D., have stepped down from the board, which is now composed of seven membe...
EyeGate Pharma Reports Full Year 2020 Financial Results and Provides B...
EyeGate Pharma Reports Full Year 2020 Financial Results and Provides Business Update WALTHAM, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced financial results for the year ended December 31, 2020 and provided an update on recent corporate and operational activities. “We are extremely pleased by our 2020 progress and our significant corporate advancem...
EyeGate Pharmaceuticals Announces Management Transition In Support of ...
EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation - Franz Obermayr, Ph.D. Appointed as Acting Chief Executive Officer, Transitioning From EVP Clinical Development - - Stephen From Elevated from Chief Executive Officer to Executive Chairman - WALTHAM, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced that Franz Obermayr, Ph.D...
- Jonathan Moreland
PRTY PARTY CITY HOLDCO INC.
ONCS ONCOSEC MEDICAL
MNR MONMOUTH REAL ESTATE INVESTMENT CORPORATION CLASS A
INTC INTEL CORPORATION
BOCH BANK OF COMMERCE HOLDINGS
AMSWA AMERICAN SOFTWARE INC. CL A
AMRS AMYRIS
ALDX ALDEYRA THERAPEUTICS
CERC CERECOR INC
CQP CHENIERE ENERGY PARTNERS L.P.
PBFX PBF LOGISTICS LP
TRUE TRUECAR INC.
IGR CBRE CLARION GLOBAL REAL ESTAT
CET CENTRAL SECURITIES CORP.
ZDGE ZEDGE
RMT ROYCE MICRO-CAP TRUST INC.
CTHR CHARLES & COLVARD LTD.
CNBKA CENTURY BANCORP INC. CL A
SPLP STEEL PARTNERS HOLDINGS LP LTD.
CLSD CLEARSIDE BIOMEDICAL INC
GBDC GOLUB CAPITAL BDC INC.
MRUS MERUS B V
OCX ONCOCYTE
REVG REV GROUP INC.
BRN BARNWELL INDUSTRIES
ALRN AILERON THERAPEUTICS
DXLG CASUAL MALE RETAIL GROUP,; INC.
GIM TEMPLETON GLOBAL INCOME FUND
GTXMQ GARRETT MOTION INC.
VTA INVESCO DYNAMIC CREDIT OPPORTU
USIO USIO INC
FCEL FUELCELL ENERGY INC.
BW BABCOCK & WILCOX ENTERPRISES
DMTK DERMTECH INC
EFT EATON VANCE FLOATING RATE INCOME TRUST
EYEG EYEGATE PHARMACEUTICALS
SI SILVERGATE CAPITAL
RILY B. RILEY FINANCIAL
FSLF THL CREDIT SENIOR LOAN FUND
BSPK BESPOKE EXTRACTS
UTZ INC.
ESOA UTZ BRANDS INC (A)
CRAWA ENERGY SERVICES OF AMERICA CORP.
YAYO CRAWFORD UNITED CORP
ARMP RIDESHARE RENTAL INC
DCOM AURUM RESOURCES CORP
DIME COMMUNITY BANCSHARES INC
- Jonathan Moreland
PBF PBF ENERGY INC. CLASS A
NRC NATIONAL RESEARCH CORPORATION
NPTN NEOPHOTONICS
JKHY JACK HENRY & ASSOCIATES INC.
IEP ICAHN ENTERPRISES L.P.
CTMX CYTOMX THERAPEUTICS INC.
CLR CONTINENTAL RESOURCES INC.
ALDX ALDEYRA THERAPEUTICS
CERC CERECOR INC
CQP CHENIERE ENERGY PARTNERS L.P.
TRUE TRUECAR INC.
AIRT AIR T INC.
UIHC UNITED INSURANCE HOLDINGS CORP.
PLSE PULSE BIOSCIENCES
SPLP STEEL PARTNERS HOLDINGS LP LTD.
HOME AT HOME GROUP INC.
CLSD CLEARSIDE BIOMEDICAL INC
GBDC GOLUB CAPITAL BDC INC.
MRUS MERUS B V
REVG REV GROUP INC.
ESTE EARTHSTONE ENERGY
CLRB CELLECTAR BIOSCIENCES
ALRN AILERON THERAPEUTICS
ODT ODONATE THERAPEUTICS INC
ROOT ROOTS
MVBF MVB FINANCIAL CORP
OFG ORIENTAL FINANCIAL GROUP
NJMC INC.
GRTS NEW JERSEY MINING CO.
VTA GRITSTONE ONCOLOGY
KFS INVESCO DYNAMIC CREDIT OPPORTU
MIRM KINGSWAY FINANCIAL SERVICES
TCON MIRUM PHARMACEUTICALS
DMTK TRACON PHARMACEUTICALS
EFT DERMTECH INC
EYEG EATON VANCE FLOATING RATE INCOME TRUST
BRKB EYEGATE PHARMACEUTICALS
CLSK BERKSHIRE HATHAWAY INC.
RILY CLEANSPARK
EGLE B. RILEY FINANCIAL
UTZ EAGLE BULK SHIPPING
SCYX UTZ BRANDS INC (A)
DNMR SCYNEXIS INC
MVEN DANIMER SCIENTIFIC
WISH INC.
MDVL THEMAVEN
ESOA INC.
TURN WRIGHT INVESTORS SERVICE HOLDINGS
SOBR INC.
MYOS RENS TECHNOLOGY INC.
ENERGY SERVICES OF AMERICA CORP.
180 DEGREE CAPITAL
SOBR SAFE
INC.
- Jonathan Moreland
EyeGate Enters Into Agreement for $8.0 Million Private Placement
EyeGate Enters Into Agreement for $8.0 Million Private Placement WALTHAM, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced that it has entered into a securities purchase agreement in connection with a private placement (the “Private Placement”) with an affiliate of Armistice Capital, LLC (“Armistice”) for aggregate gross proceeds of approximately $8.0 mi...
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma Expands Pipeline Beyond Ophthalmology with PP-001, a Clinical Stage, Best-in-Class DHODH Inhibitor PP-001 Leverages a Validated Immune Modulating Mechanism Optimized for Increased Specificity and Picomolar Potency to Avoid Off-Target Side Effects Acquisition Strengthens Leadership Team with Appointment of Panoptes Co-Founders Dr. Franz Obermayr as EVP Clinical Development and Dr. Stefan Sperl as EVP CMC and Operations WALTHAM, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“Ey...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.